Comparison of the cardiovascular effects of cisatracurium and vecuronium in patients with coronary artery disease

@article{Reich1998ComparisonOT,
  title={Comparison of the cardiovascular effects of cisatracurium and vecuronium in patients with coronary artery disease},
  author={David L. Reich and Jan Mulier and Jorgen Viby-Mogensen and Steven N. Konstadt and Hugo K. van Aken and Frank S. Jensen and Marietta DePerio and Stephen G. Buckley},
  journal={Canadian Journal of Anaesthesia},
  year={1998},
  volume={45},
  pages={794-797}
}
  • David L. Reich, Jan Mulier, +5 authors Stephen G. Buckley
  • Published in
    Canadian journal of anaesthesia = Journal…
    1998
  • DOI:10.1007/bf03012152
PurposeCisatracurium besylate (Nimbex® Injection, Glaxo Wellcome Inc., Research Triangle Park, NC) is an intermediate-acting bis-benzylisoquinolinium neuromuscular blocking drug that is one of the stereoisomers of atracurium. At doses ≤. 8 × ED95, it caused no clinically important cardiovascular side effects or histamine release in healthy patients. The purpose of the present study was to investigate the haemodynamic effects of high doses of cisatracurium in patients with coronary artery… CONTINUE READING